Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics
The global market for polymerase chain reaction (PCR) in point of care (POC) diagnostics totaled $2.9 billion in 2018 and is estimated to reach $4.8 billion by 2023, growing at a compound annual growth rate (CAGR) of 10.6% for the period of 2018-2023.
- An overview of the global market for polymerase chain reaction (PCR) in point-of-care (POC) diagnostics
- Analyses of global market trends, with data from 2015 and 2016, estimates for 2017, and projections of compound annual growth rates (CAGRs) through 2022
- Detailed analysis of point-of-care molecular diagnostics, technological trends, and governmental regulatory policies
- Examination of various segments of the POC-PCR market, including cyclers, systems, applications, and cartridges
- Patent analyses
- Company profiles of major players in the market, including Abbott Laboratories, Atlas Genetics, Cepheid Inc., Fluxergy and Roche Diagnostics
This report will cover the variety of markets being served by these newly emerging diagnostic kits, the companies that produce them, and the types of end-users who are embracing these kits. This study does not cover the existing kit market for molecular diagnostics, either through manual use or through a variety of automation platforms. These kits, which allow for processing of samples for PCR without further operator intervention, by definition, do not require much in the way of sample preparation or consumables other than what is used to generate results, so there will not be a discussion of that marketplace. However, the appropriate consumables necessary, as well as the cyclers that are paired with these kits, will be covered as a part of this report.
Todd Graham is an experienced scientist who has worked in a variety of settings throughout the biotechnology industry for more than 10 years as a key technical resource for a variety of businesses. Among his accomplishments are coordinating the roll out of a new test for a major clinical laboratory services provider, developing pre-clinical and clinical assays in support of pharmaceuticals and medical devices, and being a key team member in developing novel technologies for molecular diagnostics.